LONDON (Alliance News) - Finnish biopharmaceutical company Faron Pharmaceuticals Oy on Thursday said it has received positive top-line results from the study being carried out by its Japanese partner on its Traumakine candidate.
Faron said the top-line results from the study, conducted by licensing partner Maruishi Pharmaceutical Co Ltd, showed Traumakine was safe and well-tolerated by patients with acute respiratory distress syndrome.
Based on the results, Maruishi is now planning the next clinical trial of the drug in Japan.
"The trial results reported by Maruishi are extremely encouraging, particularly as the trial included very sick ARDS patients, yet still resulted in relatively low mortality rates. We are happy to learn that Maruishi is now planning the next pivotal clinical trial which will enable them to move towards filing of Traumakine marketing approval in Japan," said Faron Chief Executive Markku Jalkanen.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Faron Pharma (FARN)